Infinitum discloses 9.9% ArriVent BioPharma (AVBP) ownership stake

Rhea-AI Filing Summary

ArriVent BioPharma, Inc. is the subject of an amended ownership report showing that Infinitum Cayman Master Ltd, together with Infinitum Asset Management LLC and Infinitum Partners GP, LLC, beneficially owns 4,123,923 shares of ArriVent common stock, representing 9.9% of the outstanding class.

The filing states these securities are held in the ordinary course of business and not for the purpose of changing or influencing control of ArriVent. Voting and investment power over these shares is reported as sole, with no shared voting or dispositive power indicated.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

ArriVent BioPharma, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

04272N102

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 04272N102

1

Names of Reporting Persons

INFINITUM ASSET MANAGEMENT, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

FLORIDA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,123,923.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,123,923.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,123,923.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 04272N102

1

Names of Reporting Persons

Infinitum Partners GP, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,123,923.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,123,923.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,123,923.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP No. 04272N102

1

Names of Reporting Persons

Infinitum Cayman Master, Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,123,923.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,123,923.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,123,923.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ArriVent BioPharma, Inc.
(b)	Address of issuer's principal executive offices: 18 CAMPUS BLVD., SUITE 100, NEWTOWN SQUARE, PENNSYLVANIA, 19073-3269.
Item 2.
(a)	Name of person filing: Infinitum Cayman Master Ltd (Fund) Infinitum Asset Management LLC (Asset Manager) Infinitum Partners GP, LLC (GP)
(b)	Address or principal business office or, if none, residence: 201 E Las Olas Blvd, Suite 1140 Fort Lauderdale, FL 33301
(c)	Citizenship: Infinitum Cayman Master Ltd, Cayman Islands Infinitum Asset Management LLC, Delaware Infinitum Partners GP, LLC, Delaware
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 04272N102
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Infinitum Cayman Master Ltd 4,123,923 Infinitum Asset Management LLC 4,123,923 Infinitum Partners GP, LLC 4,123,923
(b)	Percent of class: Infinitum Cayman Master Ltd 9.9% Infinitum Asset Management LLC 9.9% Infinitum Partners GP, LLC 9.9%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Infinitum Cayman Master Ltd 4,123,923 Infinitum Asset Management LLC 4,123,923 Infinitum Partners GP, LLC 4,123,923
	(ii) Shared power to vote or to direct the vote: Infinitum Cayman Master Ltd 0 Infinitum Asset Management LLC 0 Infinitum Partners GP, LLC 0
	(iii) Sole power to dispose or to direct the disposition of: Infinitum Cayman Master Ltd 4,123,923 Infinitum Asset Management LLC 4,123,923 Infinitum Partners GP, LLC 4,123,923
	(iv) Shared power to dispose or to direct the disposition of:
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

INFINITUM ASSET MANAGEMENT, LLC

Signature:	John Yetimoglu
Name/Title:	Chief Investment Officer
Date:	02/17/2026

Infinitum Partners GP, LLC

Signature:	John Yetimoglu
Name/Title:	Chief Investment Officer
Date:	02/17/2026

Infinitum Cayman Master, Ltd.

Signature:	John Yetimoglu
Name/Title:	Chief Investment Officer
Date:	02/17/2026

FAQ

What ownership stake in ArriVent BioPharma (AVBP) does Infinitum report?

Infinitum reports beneficial ownership of 4,123,923 ArriVent common shares, equal to 9.9% of the class. This stake is held across Infinitum Cayman Master Ltd, Infinitum Asset Management LLC, and Infinitum Partners GP, LLC, with sole voting and dispositive power disclosed.

Which entities are listed as reporting persons for ArriVent BioPharma (AVBP)?

The filing lists Infinitum Cayman Master Ltd, Infinitum Asset Management LLC, and Infinitum Partners GP, LLC as reporting persons. Each reports the same 4,123,923 ArriVent common shares, corresponding to 9.9% of the company’s outstanding common stock.

Does Infinitum claim control intent over ArriVent BioPharma (AVBP)?

No, the certification states the securities were acquired and are held in the ordinary course of business. It adds they were not acquired and are not held for the purpose of changing or influencing control of ArriVent or in connection with any such transaction.

What voting and dispositive powers are reported for ArriVent (AVBP) shares?

Each Infinitum reporting entity discloses sole voting power and sole dispositive power over 4,123,923 ArriVent common shares. They report zero shared voting power and zero shared dispositive power, indicating exclusive authority over these particular holdings.

Why was this Schedule 13G/A filed for ArriVent BioPharma (AVBP)?

The Schedule 13G/A reflects beneficial ownership above 5% of ArriVent’s common stock. Infinitum and its related entities report a 9.9% position, triggering this passive ownership disclosure under beneficial ownership rules rather than an active control or change-of-control filing.

Who signed the ArriVent BioPharma (AVBP) ownership filing for Infinitum?

The ownership statement is signed by John Yetimoglu, identified as Chief Investment Officer. His signature appears for each of the Infinitum reporting entities, certifying that the information in the statement is true, complete, and correct to the best of his knowledge.